EP4215525A4 - Dérivé de pipérazine, son procédé de préparation et son utilisation - Google Patents
Dérivé de pipérazine, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- EP4215525A4 EP4215525A4 EP21868671.5A EP21868671A EP4215525A4 EP 4215525 A4 EP4215525 A4 EP 4215525A4 EP 21868671 A EP21868671 A EP 21868671A EP 4215525 A4 EP4215525 A4 EP 4215525A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation process
- piperazine derivative
- piperazine
- derivative
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010978095 | 2020-09-17 | ||
| CN202110597053 | 2021-05-28 | ||
| PCT/CN2021/118671 WO2022057849A1 (fr) | 2020-09-17 | 2021-09-16 | Dérivé de pipérazine, son procédé de préparation et son utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4215525A1 EP4215525A1 (fr) | 2023-07-26 |
| EP4215525A4 true EP4215525A4 (fr) | 2024-08-21 |
Family
ID=80776447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21868671.5A Pending EP4215525A4 (fr) | 2020-09-17 | 2021-09-16 | Dérivé de pipérazine, son procédé de préparation et son utilisation |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230373972A1 (fr) |
| EP (1) | EP4215525A4 (fr) |
| JP (1) | JP7700218B2 (fr) |
| CN (1) | CN116348109B (fr) |
| WO (1) | WO2022057849A1 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2184272A1 (fr) * | 2007-08-21 | 2010-05-12 | Shionogi&Co., Ltd. | Dérivé de pipérazine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2423902A1 (fr) * | 2000-09-27 | 2003-03-26 | Ajinomoto Co., Inc. | Derive de benzodiazepine |
| WO2007070816A2 (fr) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Derives de thiophene en tant qu'inhibiteurs du facteur xia |
| MX2011000755A (es) | 2008-07-28 | 2011-02-24 | Hoffmann La Roche | Derivados de diazepan y piperazina moduladores de receptores de quimiocina. |
| WO2011002067A1 (fr) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | Composé hétérocyclique et son utilisation |
| WO2011016559A1 (fr) * | 2009-08-07 | 2011-02-10 | 武田薬品工業株式会社 | Composé hétérocyclique et son utilisation |
| JP2017517512A (ja) * | 2014-05-28 | 2017-06-29 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 第xia因子インヒビター |
| CA2959987C (fr) | 2014-09-02 | 2023-05-09 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Composes de pyrazolo[3,4-c]pyridine et leurs effets contre la thrombose |
| US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| ES2754599T3 (es) * | 2015-08-05 | 2020-04-20 | Bristol Myers Squibb Co | Nuevos inhibidores de FXIa derivados de glicina sustituidos |
| RU2638155C1 (ru) | 2016-02-29 | 2017-12-12 | Общество С Ограниченной Ответственностью "Сай Фарма" | Производные бензо[d]изоксазола и их применение |
| KR20180117156A (ko) | 2016-03-02 | 2018-10-26 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클 |
| CN109563092B (zh) * | 2016-07-11 | 2021-09-14 | 坎塞拉有限公司 | 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 |
| EP3500556B1 (fr) * | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Dérivés pyridine-1-oxyde et leur utilisation en tant qu'inhbiteurs du facteur xia |
| WO2018089433A1 (fr) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | Inhibiteurs de mtorc phényle et leurs utilisations |
| US10683297B2 (en) | 2017-11-19 | 2020-06-16 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CN108863962B (zh) | 2018-07-25 | 2021-08-03 | 南京农业大学 | 一种含1-苯基-1,2,3-三氮唑结构的酰胺类化合物及其应用 |
| JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス, インコーポレイテッド | 心筋サルコメア阻害剤 |
-
2021
- 2021-09-16 EP EP21868671.5A patent/EP4215525A4/fr active Pending
- 2021-09-16 JP JP2023517672A patent/JP7700218B2/ja active Active
- 2021-09-16 CN CN202180063397.7A patent/CN116348109B/zh active Active
- 2021-09-16 US US18/027,036 patent/US20230373972A1/en active Pending
- 2021-09-16 WO PCT/CN2021/118671 patent/WO2022057849A1/fr not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2184272A1 (fr) * | 2007-08-21 | 2010-05-12 | Shionogi&Co., Ltd. | Dérivé de pipérazine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116348109B (zh) | 2025-01-21 |
| CN116348109A (zh) | 2023-06-27 |
| US20230373972A1 (en) | 2023-11-23 |
| JP2023541309A (ja) | 2023-09-29 |
| WO2022057849A1 (fr) | 2022-03-24 |
| JP7700218B2 (ja) | 2025-06-30 |
| EP4215525A1 (fr) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4385989A4 (fr) | Dérivé de sulfonamide, son procédé de préparation et son utilisation médicale | |
| EP3967687A4 (fr) | Dérivé de phénylpropénylpyridine substitué, son procédé de préparation et son utilisation médicale | |
| EP3750887A4 (fr) | Dérivé de biaryle, son procédé de préparation, et son application pharmaceutique | |
| EP3632907A4 (fr) | Dérivé de n-(azaaryl)cyclolactame-1-carboxamide, son procédé de préparation et son utilisation | |
| EP3816150A4 (fr) | Composé m-diamide, son procédé de préparation et son utilisation | |
| EP3822271A4 (fr) | Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation médicale | |
| EP4063363A4 (fr) | Dérivé pyrazolo-hétéroaryl, son procédé de préparation et son utilisation médicale | |
| EP4101437A4 (fr) | Composition bactériostatique, son procédé de préparation et son utilisation | |
| EP4349815A4 (fr) | Dérivé de 7-nitro-8-hydroxyquinoléine, son procédé de préparation et utilisation médicale associée | |
| EP3730491A4 (fr) | Dérivé d'isoxazole, son procédé de préparation et son utilisation | |
| EP3812376A4 (fr) | Conjugué de type double de paclitaxel-lipide-polysaccharide, son procédé de préparation et son utilisation | |
| EP4056571A4 (fr) | Dérivé de dihydroimidazopyrimidone tricyclique, son procédé de préparation, composition pharmaceutique et son utilisation | |
| EP4464312A4 (fr) | Oléogel, son procédé de préparation et son utilisation | |
| EP4079734A4 (fr) | Dérivé de triazolopyridazine, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante | |
| EP3819292A4 (fr) | Dérivé de phtalide, son procédé de préparation et son utilisation | |
| EP3998270A4 (fr) | Dérivé alcyne, son procédé de préparation et ses utilisations | |
| EP3660019A4 (fr) | Composé, son procédé de préparation et son utilisation | |
| EP3780098A4 (fr) | Condensateur et son procédé de préparation | |
| EP3617218A4 (fr) | Conjugué dihydroartémisinine-stéroïde, son procédé de préparation et son utilisation | |
| EP4282864A4 (fr) | Inhibiteur double cible cdk6/dyrk2, son procédé de préparation et son utilisation | |
| EP3744316A4 (fr) | Composition pharmaceutique ophtalmique, son procédé de préparation et son application | |
| EP3964518C0 (fr) | Inhibiteur de cd73, son procédé de préparation et son utilisation | |
| EP3858833A4 (fr) | Dérivé d'aminonordécane, son procédé de préparation et son utilisation | |
| EP4071170A4 (fr) | Composition pharmaceutique, son procédé de préparation et son utilisation | |
| EP3777862A4 (fr) | Composition de méloxicam, sa préparation et son procédé de préparation et son utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230317 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240719 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 471/04 20060101ALI20240715BHEP Ipc: C07D 413/14 20060101ALI20240715BHEP Ipc: C07D 405/14 20060101ALI20240715BHEP Ipc: C07D 403/14 20060101ALI20240715BHEP Ipc: C07D 401/14 20060101ALI20240715BHEP Ipc: C07D 241/08 20060101ALI20240715BHEP Ipc: A61P 7/02 20060101ALI20240715BHEP Ipc: A61K 31/4425 20060101ALI20240715BHEP Ipc: C07D 403/10 20060101AFI20240715BHEP |